190 related articles for article (PubMed ID: 35008802)
21. The metastasis suppressor, NDRG1, differentially modulates the endoplasmic reticulum stress response.
Merlot AM; Porter GM; Sahni S; Lim EG; Peres P; Richardson DR
Biochim Biophys Acta Mol Basis Dis; 2019 Sep; 1865(9):2094-2110. PubMed ID: 30981813
[TBL] [Abstract][Full Text] [Related]
22. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
[TBL] [Abstract][Full Text] [Related]
23. Down-regulation of MYCN protein by CX-5461 leads to neuroblastoma tumor growth suppression.
Taylor JS; Zeki J; Ornell K; Coburn J; Shimada H; Ikegaki N; Chiu B
J Pediatr Surg; 2019 Jun; 54(6):1192-1197. PubMed ID: 30879743
[TBL] [Abstract][Full Text] [Related]
24. Low NDRG1 mRNA expression predicts a poor prognosis in neuroblastoma patients.
Matsushita K; Uchida K; Saigusa S; Ide S; Hashimoto K; Koike Y; Otake K; Inoue M; Tanaka K; Kusunoki M
Pediatr Surg Int; 2013 Apr; 29(4):363-8. PubMed ID: 23296375
[TBL] [Abstract][Full Text] [Related]
25. The metastasis suppressor NDRG1 down-regulates the epidermal growth factor receptor via a lysosomal mechanism by up-regulating mitogen-inducible gene 6.
Menezes SV; Kovacevic Z; Richardson DR
J Biol Chem; 2019 Mar; 294(11):4045-4064. PubMed ID: 30679310
[TBL] [Abstract][Full Text] [Related]
26. Breaking the cycle: Targeting of NDRG1 to inhibit bi-directional oncogenic cross-talk between pancreatic cancer and stroma.
Geleta B; Park KC; Jansson PJ; Sahni S; Maleki S; Xu Z; Murakami T; Pajic M; Apte MV; Richardson DR; Kovacevic Z
FASEB J; 2021 Feb; 35(2):e21347. PubMed ID: 33484481
[TBL] [Abstract][Full Text] [Related]
27. Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.
Chevrier L; Meunier AC; Cochaud S; Muller JM; Chadéneau C
Int J Oncol; 2008 Nov; 33(5):1081-9. PubMed ID: 18949372
[TBL] [Abstract][Full Text] [Related]
28. Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential as a molecular target for cancer therapy.
Fang BA; Kovačević Ž; Park KC; Kalinowski DS; Jansson PJ; Lane DJ; Sahni S; Richardson DR
Biochim Biophys Acta; 2014 Jan; 1845(1):1-19. PubMed ID: 24269900
[TBL] [Abstract][Full Text] [Related]
29. Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo.
Segerström L; Baryawno N; Sveinbjörnsson B; Wickström M; Elfman L; Kogner P; Johnsen JI
Int J Cancer; 2011 Dec; 129(12):2958-65. PubMed ID: 21717457
[TBL] [Abstract][Full Text] [Related]
30. MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma.
Lau DT; Flemming CL; Gherardi S; Perini G; Oberthuer A; Fischer M; Juraeva D; Brors B; Xue C; Norris MD; Marshall GM; Haber M; Fletcher JI; Ashton LJ
Oncotarget; 2015 Jun; 6(17):15510-23. PubMed ID: 25860940
[TBL] [Abstract][Full Text] [Related]
31. MCPIP1 Exogenous Overexpression Inhibits Pathways Regulating MYCN Oncoprotein Stability in Neuroblastoma.
Boratyn E; Nowak I; Durbas M; Horwacik I; Sawicka A; Rokita H
J Cell Biochem; 2017 Jul; 118(7):1741-1755. PubMed ID: 27935099
[TBL] [Abstract][Full Text] [Related]
32. The role of NDRG1 in the pathology and potential treatment of human cancers.
Bae DH; Jansson PJ; Huang ML; Kovacevic Z; Kalinowski D; Lee CS; Sahni S; Richardson DR
J Clin Pathol; 2013 Nov; 66(11):911-7. PubMed ID: 23750037
[TBL] [Abstract][Full Text] [Related]
33. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE
Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590
[TBL] [Abstract][Full Text] [Related]
34. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
[TBL] [Abstract][Full Text] [Related]
35. Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells.
Dixon KM; Lui GY; Kovacevic Z; Zhang D; Yao M; Chen Z; Dong Q; Assinder SJ; Richardson DR
Br J Cancer; 2013 Feb; 108(2):409-19. PubMed ID: 23287991
[TBL] [Abstract][Full Text] [Related]
36. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo.
Johnsen JI; Segerström L; Orrego A; Elfman L; Henriksson M; Kågedal B; Eksborg S; Sveinbjörnsson B; Kogner P
Oncogene; 2008 May; 27(20):2910-22. PubMed ID: 18026138
[TBL] [Abstract][Full Text] [Related]
37. Two mechanisms involving the autophagic and proteasomal pathways process the metastasis suppressor protein, N-myc downstream regulated gene 1.
Sahni S; Park KC; Kovacevic Z; Richardson DR
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1361-1378. PubMed ID: 30763642
[TBL] [Abstract][Full Text] [Related]
38. The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms.
Guo ZL; Richardson DR; Kalinowski DS; Kovacevic Z; Tan-Un KC; Chan GC
J Hematol Oncol; 2016 Sep; 9(1):98. PubMed ID: 27678372
[TBL] [Abstract][Full Text] [Related]
39. SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells.
Murakami-Tonami Y; Ikeda H; Yamagishi R; Inayoshi M; Inagaki S; Kishida S; Komata Y; Jan Koster ; Takeuchi I; Kondo Y; Maeda T; Sekido Y; Murakami H; Kadomatsu K
Sci Rep; 2016 Aug; 6():31615. PubMed ID: 27539729
[TBL] [Abstract][Full Text] [Related]
40. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma.
Chava S; Reynolds CP; Pathania AS; Gorantla S; Poluektova LY; Coulter DW; Gupta SC; Pandey MK; Challagundla KB
Mol Oncol; 2020 Jan; 14(1):180-196. PubMed ID: 31637848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
